#USA #Waltham #migraine prevention #Mentari Therapeutics #Greg Divis

Exciting Leadership Change at Mentari Therapeutics

In a significant development in the biotechnology sector, Mentari Therapeutics has announced the appointment of Greg Divis as its new Chief Executive Officer and a member of the Board of Directors. This strategic move comes as the company focuses on advancing its innovative therapies aimed at preventing migraines, a condition that impacts millions globally. Effective July 20, 2026, Divis will lead the company during a crucial phase of growth and development.

Greg Divis brings a wealth of experience to Mentari, having previously served as the CEO of Avadel Pharmaceuticals. During his tenure at Avadel, he successfully guided the company through the development, FDA approval, and commercial launch of Lumryz®, a medication designed for treating narcolepsy. Divis’s leadership transformed Avadel from a developmental entity into a fully integrated commercial organization, culminating in the company’s acquisition by Alkermes for an impressive valuation of up to $2.4 billion. His track record demonstrates a strong ability to enhance shareholder value while delivering effective medical solutions, making him an ideal candidate for steering Mentari’s ambitious projects.

“Greg brings proven experience to Mentari during its foundational period of growth,” commented Julianne Bruno, Chair of the Board of Directors at Mentari Therapeutics. “He is the ideal choice to lead as we rapidly advance MT-001 and MT-002 through clinical development and position Mentari as a leader in migraine prevention.” These statements reflect the confidence the board has in Divis’s abilities to foster innovation and effectiveness within the company as it pushes forward with its pipeline of therapies.

Mentari is currently on track for key regulatory filings to support the advancement of two of its most promising products: MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both PACAP and CGRP pathways. The company plans to submit for regulatory approval for MT-001 in late FY 2026 and expects to file for MT-002 in the first quarter of 2027. Divis notes, “Mentari's approach to migraine prevention, initially targeting the complementary and validated PACAP and CGRP pathways, represents an opportunity to deliver enhanced migraine relief for patients who continue to suffer with the current standard of care.”

Under Divis's stewardship, Mentari Therapeutics is poised to become a leading entity in migraine treatment, emphasizing not only the efficacy of its therapies but also their user-friendliness; MT-002 is designed for convenient subcutaneous delivery, offering significant advantages for patient adherence and comfort.

The company’s innovative approach is further underscored by their commitment to exploring next-generation combination therapies for migraine relief, tapping into their novel drug targets. With over 1 billion individuals affected by migraines worldwide, the potential impact of Mentari’s advancements could be profound, offering hope for many who currently struggle with traditional treatment methods.

In conclusion, with a new CEO at the helm and an exciting pipeline of products on the horizon, Mentari Therapeutics is well-positioned to lead the charge in migraine prevention and treatment. Divis’s substantial industry experience and demonstrated success in developing and commercializing therapeutic innovations highlight a promising new chapter for Mentari as it seeks to enhance the quality of life for patients suffering from this debilitating condition. The upcoming years will be critical as they prepare for regulatory submissions and continue to innovate in the field of migraine treatments.

For more information about Mentari Therapeutics and its mission, please visit mentaritx.com.